氟泽雷塞是国内首个获批的KRAS G12C抑制剂。文|胡香赟编辑|海若镜来源|36氪Pro(ID:krkrpro)封面来源|劲方医药官网港股迎来今年第11家上市的创新药公司。9月19日,劲方医药在港交所挂牌,首日涨幅接近110%、市值逼近150亿。上市前一日暗盘交易涨幅均超100%,且延续了今年来创新药企业火爆的打新行情,最终申购倍数超过2200倍,金额近3500亿。此外,公司的基石投资者阵容强大...
Source Link氟泽雷塞是国内首个获批的KRAS G12C抑制剂。文|胡香赟编辑|海若镜来源|36氪Pro(ID:krkrpro)封面来源|劲方医药官网港股迎来今年第11家上市的创新药公司。9月19日,劲方医药在港交所挂牌,首日涨幅接近110%、市值逼近150亿。上市前一日暗盘交易涨幅均超100%,且延续了今年来创新药企业火爆的打新行情,最终申购倍数超过2200倍,金额近3500亿。此外,公司的基石投资者阵容强大...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.